The momentum behind GLP-1 receptor agonists has become impossible to ignore.
Originally developed to control blood glucose in diabetes, these therapies have surged to the forefront of obesity care, catalysing a fundamental shift in how we manage one of the world’s most pervasive health challenges.
With weight loss outcomes rivalling bariatric surgery and early data showing cardiovascular benefits, GLP-1s are not just reshaping patient expectations but are redrawing the commercial dynamics of the pharma sector.
This is in part driven by the immense commercial potential of GLP-1s. Evaluate data shows they will already have generated more than $50 billion globally by 2024. But we’re only at the beginning.
Check out the rest of the feature here
